Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

CAR-T Reimbursement Threatened By Medicare Coverage Analysis, Manufacturers Say

CAR T-cell therapy

Related Content

CAR-T Indication-Based Pricing May Be Evaluated In Medicare Demo

Oct 27 2017

Zevalin, Bexxar Off-Label Coverage Decision Affirms Status Quo

May 16 2005

CAR-T Therapy In Medicare: National Coverage Policy Could Come In 2019

May 18 2018

Bluebird's BCMA CAR-T Sings At ASCO, But How Will It Fly In Early Multiple Myeloma?

Jun 02 2018

CAR-T Drugs' Patient-Reported Outcomes To Be Focus Of MedCAC Meeting

Jul 10 2018

Related Companies

Novartis AG

Kite Pharma, Inc.

Bristol Myers Squibb Company

Genetix Biotherapeutics

Spectrum Pharmaceuticals, Inc.

GSK plc

Additional Topics

ImmunoOncology Pricing Strategies Market Access Reimbursement BioPharmaceutical Cancer

More from Medicare

More from Government Payers

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window